Literature DB >> 21516316

The role of LKB1 in lung cancer.

Montse Sanchez-Cespedes1.   

Abstract

In humans, the LKB1 gene is located on the short arm of chromosome 19, which is frequently deleted in lung tumors. Unlike most cancers of sporadic origin, in non-small cell lung cancer (NSCLC) nearly half of the tumors harbor somatic and homozygous inactivating mutations in LKB1. In NSCLC, LKB1 inactivation strongly predominates in adenocarcinomas from smokers and coexists with mutations at other important cancer genes, including KRAS and TP53. Remarkably, LKB1 alterations frequently occur simultaneously with inactivation at another important tumor suppressor gene, BRG1 (also called SMARCA4), which is also located on chromosome 19p. The present review considers the frequency and pattern of LKB1 mutations in lung cancer and the distinct biological pathways in which the LKB1 protein is involved in the development of this type of cancer. Finally, the possible clinical applications in cancer management, especially in lung cancer treatment, associated with the presence of absence of LKB1 are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21516316     DOI: 10.1007/s10689-011-9443-0

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  60 in total

1.  The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death.

Authors:  P Karuman; O Gozani; R D Odze; X C Zhou; H Zhu; R Shaw; T P Brien; C D Bozzuto; D Ooi; L C Cantley; J Yuan
Journal:  Mol Cell       Date:  2001-06       Impact factor: 17.970

2.  Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice.

Authors:  Hiroyuki Miyoshi; Masayuki Nakau; Tomo-o Ishikawa; Michael F Seldin; Masanobu Oshima; Makoto M Taketo
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

3.  Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Authors:  Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

4.  LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.

Authors:  Jose M Lizcano; Olga Göransson; Rachel Toth; Maria Deak; Nick A Morrice; Jérôme Boudeau; Simon A Hawley; Lina Udd; Tomi P Mäkelä; D Grahame Hardie; Dario R Alessi
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

5.  Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer.

Authors:  A Ylikorkala; E Avizienyte; I P Tomlinson; M Tiainen; S Roth; A Loukola; A Hemminki; M Johansson; P Sistonen; D Markie; K Neale; R Phillips; P Zauber; T Twama; J Sampson; H Järvinen; T P Mäkelä; L A Aaltonen
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

Review 6.  Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status.

Authors:  D Grahame Hardie
Journal:  Endocrinology       Date:  2003-09-04       Impact factor: 4.736

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

8.  Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.

Authors:  Esther Conde; Barbara Angulo; Moying Tang; Manuel Morente; Juan Torres-Lanzas; Angel Lopez-Encuentra; Fernando Lopez-Rios; Montserrat Sanchez-Cespedes
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

9.  Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.

Authors:  Regan M Memmott; Joell J Gills; Melinda Hollingshead; Margaret C Powers; Zhiping Chen; Bruce Kemp; Alan Kozikowski; Phillip A Dennis
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  26 in total

1.  A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.

Authors:  Lu Chen; Brienne E Engel; Eric A Welsh; Sean J Yoder; Stephen G Brantley; Dung-Tsa Chen; Amer A Beg; Chunxia Cao; Frederic J Kaye; Eric B Haura; Matthew B Schabath; W Douglas Cress
Journal:  J Thorac Oncol       Date:  2016-02-23       Impact factor: 15.609

2.  Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion.

Authors:  Alessandra M Richardson; Lauren S Havel; Allyson E Koyen; Jessica M Konen; John Shupe; W G Wiles; W David Martin; Hans E Grossniklaus; Gabriel Sica; Melissa Gilbert-Ross; Adam I Marcus
Journal:  Clin Cancer Res       Date:  2017-12-05       Impact factor: 12.531

3.  Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.

Authors:  Matthew B Schabath; Douglas Cress; Teresita Munoz-Antonia
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

Review 4.  Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.

Authors:  Rita Nahta; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Rafaela Andrade-Vieira; Sarah N Bay; Dustin G Brown; Gloria M Calaf; Robert C Castellino; Karine A Cohen-Solal; Annamaria Colacci; Nichola Cruickshanks; Paul Dent; Riccardo Di Fiore; Stefano Forte; Gary S Goldberg; Roslida A Hamid; Harini Krishnan; Dale W Laird; Ahmed Lasfar; Paola A Marignani; Lorenzo Memeo; Chiara Mondello; Christian C Naus; Richard Ponce-Cusi; Jayadev Raju; Debasish Roy; Rabindra Roy; Elizabeth P Ryan; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Renza Vento; Jan Vondráček; Mark Wade; Jordan Woodrick; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 5.  Metformin: a new option in cancer treatment.

Authors:  Cristóbal Belda-Iniesta; Olga Pernía; Rafael Simó
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

6.  A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway.

Authors:  Jui-Ling Hsu; Shih-Ping Liu; Chia-Chung Lee; Lih-Ching Hsu; Yunn-Fang Ho; Hsu-Shan Huang; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-09       Impact factor: 3.000

7.  cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.

Authors:  Zirong Chen; Jian-Liang Li; Shuibin Lin; Chunxia Cao; Nicholas T Gimbrone; Rongqiang Yang; Dongtao A Fu; Miranda B Carper; Eric B Haura; Matthew B Schabath; Jianrong Lu; Antonio L Amelio; W Douglas Cress; Frederic J Kaye; Lizi Wu
Journal:  J Clin Invest       Date:  2016-05-03       Impact factor: 14.808

8.  Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression.

Authors:  Ruirui Kong; Fengshuang Yi; Pushuai Wen; Jianghong Liu; Xiaoping Chen; Jinqi Ren; Xiaofei Li; Yulong Shang; Yongzhan Nie; Kaichun Wu; Daiming Fan; Li Zhu; Wei Feng; Jane Y Wu
Journal:  J Clin Invest       Date:  2015-11-03       Impact factor: 14.808

9.  LKB1 controls human bronchial epithelial morphogenesis through p114RhoGEF-dependent RhoA activation.

Authors:  Xiaojian Xu; Dan Jin; Joanne Durgan; Alan Hall
Journal:  Mol Cell Biol       Date:  2013-05-06       Impact factor: 4.272

Review 10.  C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma.

Authors:  Benedikte Jacobsen; Mette Camilla Kriegbaum; Eric Santoni-Rugiu; Michael Ploug
Journal:  World J Clin Oncol       Date:  2014-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.